The CD123 antibody-drug conjugate pivekimab sunirine exerts profound activity in preclinical models of pediatric acute lymphoblastic leukemia.
Saved in:
| Title: | The CD123 antibody-drug conjugate pivekimab sunirine exerts profound activity in preclinical models of pediatric acute lymphoblastic leukemia. |
|---|---|
| Authors: | Watts B; Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, UNSW Medicine & Health, UNSW Centre for Childhood Cancer Research UNSW Sydney Sydney New South Wales Australia., Smith CM; Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, UNSW Medicine & Health, UNSW Centre for Childhood Cancer Research UNSW Sydney Sydney New South Wales Australia., Evans K; Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, UNSW Medicine & Health, UNSW Centre for Childhood Cancer Research UNSW Sydney Sydney New South Wales Australia., Gifford AJ; Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, UNSW Medicine & Health, UNSW Centre for Childhood Cancer Research UNSW Sydney Sydney New South Wales Australia.; Anatomical Pathology, NSW Health Pathology Prince of Wales Hospital Randwick New South Wales Australia.; School of Clinical Medicine, UNSW Medicine & Health UNSW Sydney Sydney New South Wales Australia., Mohamed SMA; Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, UNSW Medicine & Health, UNSW Centre for Childhood Cancer Research UNSW Sydney Sydney New South Wales Australia.; Department of Pharmaceutics and Industrial Pharmacy Faculty of Pharmacy, Ain Shams University Cairo Egypt., Erickson SW; RTI International Research Triangle Park North Carolina USA., Earley EJ; RTI International Research Triangle Park North Carolina USA., Neuhauser S; The Jackson Laboratory for Mammalian Genetics Bar Harbor Maine USA., Stearns TM; The Jackson Laboratory for Mammalian Genetics Bar Harbor Maine USA., Philip VM; The Jackson Laboratory for Mammalian Genetics Bar Harbor Maine USA., Chuang JH; The Jackson Laboratory for Genomic Medicine Farmington Connecticut USA., Zweidler-McKay PA; ImmunoGen, Inc. Waltham Massachusetts USA., Lakshmikanthan S; ImmunoGen, Inc. Waltham Massachusetts USA., Jocoy EL; The Jackson Laboratory Sacramento California USA., Bult CJ; The Jackson Laboratory for Mammalian Genetics Bar Harbor Maine USA., Teicher BA; National Cancer Institute Bethesda Maryland USA., Smith MA; National Cancer Institute Bethesda Maryland USA., Lock RB; Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, UNSW Medicine & Health, UNSW Centre for Childhood Cancer Research UNSW Sydney Sydney New South Wales Australia. |
| Source: | HemaSphere [Hemasphere] 2025 Jan 17; Vol. 9 (1), pp. e70063. Date of Electronic Publication: 2025 Jan 17 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 101740619 Publication Model: eCollection Cited Medium: Internet ISSN: 2572-9241 (Electronic) Linking ISSN: 25729241 NLM ISO Abbreviation: Hemasphere Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
